Tandem Diabetes Care Exceeds $1B Sales, Prepares Three New Pump Launches
Tandem Diabetes Care exceeded $1 billion in 2025 sales, launched Control-IQ Plus, t:slim X2 compatibility with FreeStyle Libre and Android control for Mobi. It will launch an international Mobi rollout, U.S. Mobi with FreeStyle Libre 3 Plus and global Dexcom 15-day sensor integration on its pumps.
1. 2025 Sales Milestone
Tandem Diabetes Care closed 2025 with over $1 billion in worldwide revenue, marking its strongest annual performance to date. This milestone reflects growing demand for its automated insulin delivery systems and strengthened market position in the diabetes technology sector.
2. Recent Product Developments
In late 2025, Tandem rolled out its Control-IQ Plus algorithm to enhance automated glucose control and introduced t:slim X2 pump compatibility with Abbott’s FreeStyle Libre. The company also launched Android-based remote control for its portable Mobi pump, broadening user flexibility.
3. Future Launch Plan
Tandem is gearing up for three major releases: an international rollout of the Mobi pump, a U.S. launch of Mobi integrated with FreeStyle Libre 3 Plus, and global integration of Dexcom’s 15-day continuous glucose sensor across its pump and software platforms. These initiatives aim to expand its addressable market and drive further revenue growth.